Corcept Therapeutics Incorporated (CORT)
CORT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1088856/000162828026011091/0001628280-26-011091-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | CORT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2004 |
| SEC CIK | 0001088856 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $761.4M |
| Net income | $99.7M |
| Operating income | $44.8M |
| Net margin | 13.1% |
| Operating margin | 5.9% |
| Revenue growth | +12.8% |
| Cash | $120.5M |
| Total assets | $836.7M |
| P/E (computed) | 76.0× |
| P/S (computed) | 9.9× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-03 |
| Cash and burn | $98.7M cash; operating cash flow $49.5M a quarter. | Report 2026-09-30 |
| Shares outstanding | 109,443,109 (2026-10-22); 105,188,217 a year earlier; 103,081,357 three years earlier. | Cover page 2026-10-22 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, San Mateo, California, United States | PCAOB Form AP 2026-03-17 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $3.3M, sold $102.5M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $340.5M | $126.8M | $142.9M | $98.7M | No debt tags | $963.6M | 10-Q 2026-11-03 |
| Q2 2026 2026-06-30 | $256.1M | $43.0M | $33.5M | $111.0M | No debt tags | $830.8M | 10-Q 2026-07-29 |
| Q1 2026 2026-03-31 | $164.9M | -$31.8M | -$16.8M | $108.7M | No debt tags | $769.1M | 10-Q 2026-04-30 |
| Q4 2025 2025-12-31 | $202.1M | $24.3M | $38.4M | $120.5M | No debt tags | $761.4M | 10-K 2026-02-24 |
| Q3 2025 2025-09-30 | $207.6M | $19.7M | $54.5M | $125.1M | No debt tags | $741.2M | 10-Q 2026-11-03 |
| Q2 2025 2025-06-30 | $194.4M | $35.1M | $44.3M | $102.7M | No debt tags | $716.1M | 10-Q 2026-07-29 |
| Q1 2025 2025-03-31 | $157.2M | $20.5M | $4.8M | $89.8M | No debt tags | $685.4M | 10-Q 2026-04-30 |
| Q4 2024 2024-12-31 | $181.9M | $30.7M | $60.1M | $127.7M | No debt tags | $675.0M | 10-K 2026-02-24 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM S-3 | S-3 | 2017-03-13 |
| Latest annual report | 10-K | 2026-02-24 |
| Latest quarterly / interim | 10-Q | 2026-11-03 |
| Latest current report | 8-K | 2026-11-03 |
| Latest proxy | DEF 14A | 2026-04-17 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +0.2% |
| 1 month | -38.1% |
| 3 months | -34.0% |
| Year to date | +109.6% |
| 1 year | -3.7% |
| From 52-week high | -41.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals Inc. | $107.48 | -6.56% | $7.5B |
| CYTK | Cytokinetics Incorporated | $53.17 | -5.27% | $7.4B |
| KNSA | Kiniksa Pharmaceuticals International plc | $94.23 | -2.18% | $7.4B |
| AMRX | Amneal Pharmaceuticals Inc. | $21.23 | -0.70% | $7.4B |
| ALKS | Alkermes plc | $46.53 | -1.06% | $7.8B |
| ABVX | Abivax SA | $83.61 | -4.53% | $7.3B |
| AXSM | Axsome Therapeutics Inc. | $137.01 | -3.30% | $7.2B |
| PTGX | Protagonist Therapeutics Inc. | $124.83 | -4.67% | $8.1B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier